Drug intelligence / Profile preview

MTX-439

Development stage: Phase 1
Lead developer: Mediar Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

MTX-439 is a monoclonal antibody developed by Mediar Therapeutics specifically designed to treat fibrosis associated with chronic kidney disease (CKD). It targets Discoidin Domain Receptor 1 (DDR1), a collagen-activated receptor tyrosine kinase that plays a critical role in the activation of myofibroblasts and the subsequent deposition of extracellular matrix. By inhibiting the DDR1 signaling pathway, MTX-439 aims to disrupt the fibrotic cascade, potentially halting or reversing the progression of kidney damage. The drug is part of Mediar's portfolio of myofibroblast-targeting therapies, which focus on addressing the underlying drivers of fibrotic disease rather than just the inflammatory symptoms.

Targets

DDR1 (Discoidin domain receptor 1)

Beyond the preview

Go deeper on MTX-439.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MTX-439.

Explore the full profile